Selected article for: "detection limit and HBV detection"

Author: Chen, Xu; Wang, Shoshi; Tan, Yan; Huang, Junfei; Yang, Xingui; Li, Shijun
Title: Nanoparticle-Based Lateral Flow Biosensors Integrated With Loop-Mediated Isothermal Amplification for the Rapid and Visual Diagnosis of Hepatitis B Virus in Clinical Application
  • Cord-id: 7kj52uru
  • Document date: 2021_9_14
  • ID: 7kj52uru
    Snippet: Hepatitis B virus (HBV) infection remains one of the major public health issues worldwide. Developing a rapid, sensitive, specific, easy-to-operate, and cost-saving approach for the diagnosis of HBV is essential for its therapy and prevention. Here, we first devised a novel approach, termed “loop-mediated isothermal amplification integrated with a nanoparticle-based lateral flow biosensor (LAMP-LFB),” for the detection of HBV in clinical application. The results indicated that a set of LAMP
    Document: Hepatitis B virus (HBV) infection remains one of the major public health issues worldwide. Developing a rapid, sensitive, specific, easy-to-operate, and cost-saving approach for the diagnosis of HBV is essential for its therapy and prevention. Here, we first devised a novel approach, termed “loop-mediated isothermal amplification integrated with a nanoparticle-based lateral flow biosensor (LAMP-LFB),” for the detection of HBV in clinical application. The results indicated that a set of LAMP primers based on the S gene were valid for the establishment of HBV-LAMP-LFB. The optimal HBV-LAMP can be carried out at a constant temperature of 65°C for 40 min. The whole detection process, including HBV genomic DNA preparation (∼10 min), LAMP (40 min), and LFB reading (within 2 min), can be accomplished within 60 min. The limit of detection of the HBV-LAMP-LFB assay was 7.5 IU per test. The specificity of this assay was one hundred percent, and there was no cross-reactivity with other pathogens. Hence, these results indicated that the HBV-LAMP-LFB assay established in the current study is a sensitive, rapid, specific, visual, simple, and cost-saving method for the screening of HBV agents. More importantly, the HBV-LAMP-LFB has remarkable potential to develop a point-of-care testing in clinical application, especially in resource-scarce regions.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute hepatitis: 1
    • absence presence and acute liver: 1, 2, 3, 4, 5
    • absence presence and acute liver failure: 1
    • absence presence and liver cirrhosis: 1, 2, 3, 4, 5
    • absence presence and liver cirrhosis cancer: 1
    • absence presence and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and lod detection: 1
    • absence presence and lod detection limit: 1
    • absence presence and low sensitivity: 1, 2, 3, 4, 5, 6, 7
    • acid amplification and acute hepatitis: 1
    • acid amplification and acute liver: 1
    • acid amplification and acute liver failure: 1
    • acid amplification and liver cirrhosis: 1
    • acid amplification and liver cirrhosis cancer: 1
    • acid amplification and liver disease: 1, 2
    • acid amplification and lod detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acid amplification and lod detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acid amplification and low equipment cost: 1, 2, 3, 4, 5
    • acid amplification and low sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20